---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-085580"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T22:12:18.486454+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Passage Bio board change: director resigns, new director Dolan Sondhi appointed

## Summary
- Thomas Woiwode resigned from Board and Compensation Committee effective July 26, 2023; no disagreement cited.
- Board appointed Dr. Dolan Sondhi as Class II director effective July 27, 2023, filling a vacancy.
- Dr. Sondhi is Professor of Research in Genetic Medicine at Weill Cornell, with gene therapy expertise.
- Received non-incentive stock options for 48,000 shares vesting over three years under 2020 Equity Plan.
- Also appointed to the Nominating and Corporate Governance Committee.

## SEC filing metadata
- accession: 0001104659-23-085580
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/tm2322324d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-085580
- JSON: https://secwatch.observer/filing/0001104659-23-085580.json
- Plain text: https://secwatch.observer/filing/0001104659-23-085580.txt

## Key facts
- Executive change
  Dolan Sondhi was appointed as Director at Passage BIO, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “ Governance Committee ”), appointed Dr. Dolan Sondhi as a Class II director to fill a Board vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm
- Executive change
  Thomas Woiwode resigned as Director at Passage BIO, Inc..
  - Action: resigned
  - Role: Director
  source text: Thomas Woiwode, Ph.D., notified Passage Bio, Inc. (the “ Company ”) of his decision to resign from the Company’s Board of Directors (the “ Board ”), including from the Compensation Committee of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000110465923085580/0001104659-23-085580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.